Articles

The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients. Read More ›

IWTI Ovarian Cancer

The Role of Genetic Testing in Patients with Ovarian Cancer

By Amina Ahmed, MD; Paula Anastasia, MN, RN, AOCN; Ali McBride, PharmD, MS, BCPS

Interview with the Innovators, Video

Videos

Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. Read More ›

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

FDA Updates, Lung Cancer

Web Exclusives

On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication. Read More ›

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Updates

Web Exclusives

On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer. Read More ›

From The Editor

By Beth Faiman, PhD, APRN-BC, AOCN

From the Editor

TON - June 2020, Vol 13, No 3

AVBCC 2019 Highlights

TON - June 2020, Vol 13, No 3

Cancer Center Profile

TON - June 2020, Vol 13, No 3

Mayo Clinic is one of the largest providers of bone marrow transplants in the United States, having performed nearly 10,000 stem-cell transplants at its campuses in Arizona, Florida, and Minnesota. At Mayo Clinic in Rochester, MN, approximately 500 transplants are performed each year. Read More ›

First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma

By Phoebe Starr

Renal Cell Carcinoma

TON - June 2020, Vol 13, No 3